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A B S T R A C T
The aim of this investigation was to assess the rate and appropriate use of fresh frozen plasma (FFP) at the Clinical
Hospital Center Rijeka in two six-month periods, at an interval of 5 years, before and after introducing clinical stan-
dards for transfusion practice and hemovigilance, and to evaluate the results of applied measures. We studied 315 pa-
tients transfused with 1341 doses of FFP in two six-month periods from September to February of 1999/2000 and
2004/2005. The first period (1999/00) of the study was retrospective and 226 patients were transfused with 928 FFP
units. The second period (2004/05) was prospective and we studied 89 patients transfused with 413 units. In the first pe-
riod blood bank records were retrospectively reviewed and in the second period all FFP requests, performed coagulation
tests and transfusion episodes were prospectively analyzed. The number of inappropriate transfusions decreased from
39.8% to 23.6%. In most patients (85.1%), coagulation tests were made prior to FFP transfusion. The number of patients
transfused with one and two FFP doses decreased, while those transfused with three or more doses increased. Most of the
appropriately transfused patients were those with active bleeding due to coagulation factor deficiency and massive trans-
fusions. The least were those requiring reversal of warfarin effect. Our results demonstrated a decrease in the number of
patients treated with FFP in the second period. The introduction of clinical standards of good transfusion practice and
hemovigilance showed positive effects. Considering that there was a number of inappropriately transfused patients con-
tinued education of all health personnel engaged in transfusion treatment is evidently necessary.
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Introduction
Transfusion of components derived from human blood
underpins modern medicine. However, transfusion is not
without risks. Furthermore, there is a lack of consensus
among clinicians on the criteria of the appropriate use.
Fresh frozen plasma (FFP) is a blood product pro-
duced from human plasma, separated from donated whole
blood after centrifugation and frozen rapidly to –30°C or
bellow within six hours after collection1, or from plas-
maphaeresis. Therefore, FFP is a good source of coagula-
tion factors including labile factors V and VIII. In Cro-
atia, FFP is not pathogen reduced. The production and
distribution of drugs and consequently of blood products
is regulated by laws, rules and recommendations2–8.
A high rate of inappropriate use of FFP is a signifi-
cant problem worldwide, both in the developed and de-
veloping countries9–13. Inappropriate use not only leads
to a wastage of limited resources thus depriving more
needy patients of their use, it also leads to increased
healthcare costs and risk of transfusion related complica-
tions such as viral transmission, which could cause sig-
nificant morbidity and mortality. The relative risk of
death within 10 years increases by 7.3% per unit of
FFP14. Therefore, the expected benefits of FFP therapy
should exceed the possible risk.
Indications for transfusing FFP are very limited5–8,15–22.
The current national guidelines fulfill all conditions for
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the appropriate use of FFP, i.e. the presence of bleeding
or invasive procedure with coagulopathy or multiple fac-
tor-deficiencies due to conditions such as disseminated
intravascular coagulation (DIC), liver failure, massive
transfusion, emergency reversal of warfarin effect, over-
-anticoagulation with warfarin, prolongation of prothro-
mbin time (PT) or activated partial thromboplastin time
(APTT) to 1.5 times that of normal control and as the re-
placement fluid in plasma exchange for thrombotic throm-
bocytopenic purpura (TTP) or the hemolytic-uremic syn-
drome (HUS). The primary method for documenting a
coagulation factor deficiency is by measuring PT and
APTT.
FFP is absolutely contraindicated in patients with
IgA deficiency or in patients with hypersensitivity to
plasma proteins. FFP is not indicated in DIC or anticoag-
ulant reversal without bleeding. There are some situa-
tions in which FFP is inappropriately used such as volu-
me resuscitation expander, nutritional support in protein
losing states like burns and in plasma exchange proce-
dures for conditions other than TTP and HUS.
Each unit of FFP raises the factor level in an adult by
3%–5%. As a result, 1–2 units are an insufficient dose in
adult patients with significant coagulopathy. The recom-
mended dosage is 10–20 mL of plasma per kg of body
weight corresponding to 4–6 units in a 70 kg adult, but it
could be exceeded in massive bleeding.
Response to FFP transfusion should be monitored
through the measurement of coagulation activities by
traditional laboratory techniques (PT, APTT and the
level of coagulation factors) and the clinical state of
patients15. Therefore, the coagulation parameters should
be measured before and after FFP transfusion to record
the degree of correction. If FFP is given to a bleeding pa-
tient, the clinical response may be the best indication of
transfusion effectiveness.
Transfusion reactions appear in 3%–5% of transfused
patients16. The largest avoidable risk to patients from
transfusion is probably due to the transfusion of FFP for
inappropriate or unproven clinical indications. Allergic
reactions and anaphylaxis, transfusion related acute lung-
-injury (TRALI), hemolysis from transfused antibodies to
blood group antigen, especially ABO antibodies, transfu-
sion associated circulatory overload (TACO) and infec-
tions (freezing does not remove free viruses such as hep-
atitis A, B, C, human immunodeficiency virus and par-
vovirus B19)23 are of particular concern.
Various strategies are used worldwide to reduce inap-
propriate use of blood products. These include adminis-
trative interventions, such as the screening of requests
by hematologists or transfusion specialists, by using the
request forms that incorporate appropriate indications
as reminders for clinicians, clinical audit cycles and edu-
cation for health care staff.
The aim of this study was to compare the appropriate-
ness of FFP transfusion at the Clinical Hospital Center
Rijeka, a tertiary care teaching hospital with 1191 beds,
in two different six-months periods: from September
1999 to February 2000, and in the same period 5 years
later, after the implementation of clinical transfusion
practice, education and hemovigilance.
Materials and Methods
All patients (n=315) transfused with FFP, with the
exception of pediatric, from September 1999 to February
2000 and from September 2004 to February 2005 were
enrolled into this study. The first period (1999/00) of the
study was retrospective and 226 patients were trans-
fused with 928 FFP units. The second period (2004/05)
was prospective and 89 patients transfused with 413
units were studied. In the first period blood bank records
were retrospectively reviewed and in the second period
all FFP requests and transfusion episodes were prospec-
tively analyzed. The recorded data included department
requests for FFP, patient’s presenting problems, reasons
for FFP request, date of transfusion, number of units
transfused and coagulation profile of patient (before and
after FFP use) if available.
Assessment of the appropriateness of FFP use was
made conforming to the national guidelines that are con-
sistent with the European Guidelines5. The judgment of
appropriate usage was mainly based on the patient’s di-
agnosis, clinical indications, (e.g., active bleeding, emer-
gency surgery or invasive procedure) and pretransfusion
coagulation results as well as adequate dosage.
Transfusions were assigned into three categories: ap-
propriate, inappropriate or possibly appropriate. The lat-
ter included cases for which there was insufficient infor-
mation to fully asses the episode, and those situations in
which the indication for the use of blood components was
controversial. When reasons for transfusion were un-
clear (missing laboratory parameters or clinical data),
transfusion was considered inappropriate.
All data were assembled into a database created by
the MS Excel program and statistically analyzed on a PC
using the Statistical Data Analysis Software System, Ver-
sion 7.1 StatSoft Inc.2005. Categorical outcome variables
were compared between two groups based on the c2-test
or Fisher’s exact test (where the p value <0.05 was con-
sidered statistically significant).
Results
During the first study period a total of 928 units of
FFP and 4549 units of PRBC were issued (ratio 0.2:1).
Five years later a total of 413 FFP units and 4383 PRBC
were transfused (0.09 FFP per 1 PRBC). The ratio of
FFP and PRBC use was an indicator of the quality of
transfusion therapy when comparing the two different
periods.
We studied 315 patients transfused with 1341 doses of
FFP in two six-month periods. In the first period 226 pa-
tients were transfused with 928 FFP units and 89 pa-
tients with 413 units in the second period. There was no
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change of hospital regimen and diagnosis pattern in the
two periods.
The distribution of patients who received FFP by op-
erating service is shown in Figure 1. Internal medicine
patients accounted for most of the cases (48%) with sur-
gery patients representing the second largest percentage
(30%). The third major user was the Intensive Care
Units (18%).
An analysis of appropriateness of FFP usage in two
different periods, according to national guidelines, is
shown in Table 1. In the first period appropriate usage of
FFP was found in 51.8% of patients, probably appropri-
ate in 8.4% and inappropriate usage in 39.8%. Five years
later FFP transfusions were judged appropriate for 67.4%
of patients, probably appropriate for 9.0% and inappro-
priate for 23.6%. If we compare the appropriateness of
FFP usage in both periods, the difference is statistically
significant (c2=7.62, df=4; p=0.022), the number of pa-
tients appropriately transfused increased from 51.8% to
67.4%, and consequently, those treated inadequately de-
creased from 39.8% to 23.6%.
The laboratory assessment before FFP transfusion is
shown in Table 2. There is no significant difference be-
tween both periods (p=0.806). The majority of patients
had coagulation tests before FFP usage (85.4% in the
first and 84.3% in the second period).
Analysis of post-FFP treatment coagulation tests done
in patients in different periods are shown in Table 3.
Laboratory assessment of post FFP transfusion was per-
formed in 32.1% of patients in the first period and in
33.3% of patients five years later, so the difference is in-
significant (p=0.839).
Evaluation of FFP usage according to the number of
transfused units in different periods is shown in Table 4.
The total number of treated patients with respect to the
number of transfused FFP units was statistically differ-
ent by periods (c2=11.248; df=2; p=0.004). In the first
period 4.9% of patients received one FFP unit, 47.3% re-
ceived two units while 47.8% received three or more
units. Five years later only 2.3% patients were trans-
fused with a single unit, 29.2% with two and 68.5% with
three or more units of FFP.
An analysis of the patients transfused with FFP for
appropriate indications such as hemorrhagic diathesis,
massive transfusion and warfarin reversal are listed in
Table 5. The transfusion of FFP did not differ signifi-
cantly in the two different periods regarding the reasons
for FFP use (c2=2.37; df=2; p=0.306). The most com-
mon reason for FFP usage in both periods was hemor-
rhagic diathesis (61.5% and 70.0% of patients respecti-
vely), followed by massive transfusion (32.5% and 21.7%
of patients) and warfarin reversal (6.0% and 8.3% of pa-
tients).
Discussion
Clinical practice is characterized by great variations
in the use of FFP. Findings from a 1991 retrospective
audit showed that FFP was used inappropriately in 60%










Fig. 1. Distribution by departments of patients treated with fresh
frozen plasma.
TABLE 1
APPROPRIATENESS OF FFP USAGE
Appropriateness of FFP usage
(Number and % of the patients) Total
Appropriate Probably appropriate Inappropriate
Period
1999/00
Count 117 19 90 226
Expected count 127 19.4 79.6 226.0
Row % 51.8% 8.4% 39.8% 100.0%
Column% 66.1% 70.4% 81.1% 71.7%
2004/05
Count 60 8 21 89
Expected count 50.0 7.6 31.4 89.0
Row % 67.4% 9.0% 23.6% 100.0%
Column% 33.9% 29.6% 18.9% 28.3%
Total
Count 177 27 111 315
Expected count 177.0 27.0 111.0 315.0
Row % 56.2% 8.6% 35.2% 100.0%
Column% 100.0% 100.0% 100.0% 100.0%
p=0.022, FFP – fresh frozen plasma
of cases. In Croatia in 1992 even 50% to 80% of FFP was
not used in compliance with the approved indications24.
Recent studies often show unjustifiable use of FFP
but published data differs considerably. Belgian Univer-
sity Hospital records demonstrated that the use of FFP
was not indicated in 67% of the patients25 and in New
Zealand in 33%26.
The appearance of the variant Creutzfeldt-Jacobs dis-
ease and other viruses like the West Nile virus, and rising
concerns regarding their transmission through blood
transfusion are crucial to evaluate and optimize blood
component usage and reduce wastage, especially FFP27.
Inappropriate transfusion of FFP represents the largest
risk for transfused patients that could be avoided by re-
specting the indications for use28.
In many countries, including Europe and the United
States, the use of blood products continued to rise in the
last two decades, especially the use of FFP relative to
packed red blood cells (PRBC)29,30. Soutar has reported
that the use of FFP has increased 2% annually for the
past 5 years31.
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TABLE 2
PRE-FFP TREATMENT COAGULATION TESTS
Pre-FFP treatment coagulation tests
(Number and % of the patients) Total
Not available Available
Count 33 193 226
1999/00
Expected Count 33.7 192.3 226.0
Row% 14.6% 85.4% 100.0%
Period
Column% 70.2% 72.0% 71.8%
Count 14 75 89
2004/05
Expected Count 13.3 75.7 89
Row% 15.7% 84.3% 100.0%
Column% 29.8% 28.0% 28.2%
Count 47 268 315
Total
Expected Count 47.0 268.0 315.0
Row% 14.9% 85.1% 100.0%
Column% 100.0% 100.0% 100.0%
p=0.806, FFP – fresh frozen plasma
TABLE 3
POST-FFP TREATMENT COAGULATION TESTS
Post-FFP treatment coagulation tests




Count 131 62 193
Expected count 130.3 62.7 193.0
Row % 67.9% 32.1% 100.0%
Column% 72.4% 71.3% 72.0%
2004/05
Count 50 25 75
Expected count 50.7 24.3 75.0
Row % 66.7% 33.3% 100.0%
Column% 27.6% 28.7% 28.0%
Total
Count 181 87 268
Expected count 181.0 87.0 268.0
Row % 67.5% 32.5% 100.0%
Column% 100.0% 100.0% 100.0%
p=0.839, FFP – fresh frozen plasma
The diversity of available data induced us to investi-
gate the FFP consumption in our hospital and whether
there was an increase during the studied five-year pe-
riod. We were also interested in finding out whether the
introduction of clinical transfusion practice, education
and the control of transfusion therapy affected the use of
FFP.
During the first study period from September 1999 to
February 2000 a total of 928 units of FFP (approximately
215 liters) and 4549 units of PRBC were issued. The vol-
ume of red cell units transfused was used as denominator
to allow comparison of FFP use between the two studied
periods in our hospital and interhospital comparison, as
well as comparison with other references. In the first pe-
riod this FFP/PRBC ratio was 0.2:1, which corresponds
to Soutar’s data31. Five years later a total of 413 FFP
units were transfused (approximately 100 liters) and
4383 PRBC, consequently 0.09 FFP per 1 PRBC indicat-
ing a tendency of decrease of FFP use. Similar results
were obtained in Spain32.
Tuckfield et al. showed that rates of inappropriate
FFP transfusion episodes fell significantly from 31% to
15% after blood product request forms were modified to
incorporate indications for transfusion and relevant clin-
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TABLE 4
THE USAGE OF FFP ACCORDING TO THE NUMBER OF TRANSFUSED UNITS
Number and % of the patients transfused with
Total
1 FFP unit 2 FFP units 3<FFP units
Count 11 107 108 226
1999/00 Expected Count 9.3 95.4 121.3 226.0
Row % 4.9% 47.3% 47.8% 100.0%
Period
Column % 84.6% 80.4% 63.9% 71.8%
Count 2 26 61 89
2004/05
Expected Count 3.7 37.6 47.7 89.0
Row % 2.3% 29.2% 68.5% 100.0%
Column % 15.4% 19.6% 36.1% 28.2%
Count 13 133 169 315
Total
Expected Count 13.0 133.0 169.0 315.0
Row % 4.1% 42.% 53.7% 100.0%
Column % 100.0% 100.0% 100.0% 100.0%
p=0.004, FFP – fresh frozen plasma
TABLE 5
REASONS FOR APPROPRIATE USE OF FFP
Reasons for use of FFP
(Number and % of the patients) Total
Hemorrhagic diathesis Massive transfusion Warfarin reversal
Count 72 38 7 117
1999/00
Expected Count 75.4 33.7 7.9 117.0
Row % 61.5% 32.5% 6.0% 100.0%
Period
Column % 63.2% 74.5% 58.3% 66.1%
Count 42 13 5 60
2004/05
Expected Count 38.6 17.3 4.1 60.0
Row % 70.0% 21.7% 8.3% 100.0%
Column % 36.8% 25.5% 41.7% 33.9%
Count 114 51 12 177
Total
Expected Count 114.0 51.0 12.0 177.0
Row % 64.4% 28.8% 6.8% 100.0%
Column % 100.0% 100.0% 100.0% 100.0%
p=0.306, FFP – fresh frozen plasma
ical and laboratory data, and monitored for confirmation
with applicable transfusion guidelines33. Similar results
were obtained by Hawkins et al. who found that 33% of
transfused units were given inappropriately26. After a
five year implementation of clinical transfusion practice
at our hospital, which included screening of requests by
transfusion specialists, using the request forms that in-
corporate laboratory data and clinical diagnosis, consul-
tations with the prescribers, clinical audit cycles and ed-
ucation for health care staff, there was a significant
decrease of unjustified FFP treatment from the 39.8% in
the first period to 23.6%.
The standard dose of FFP is 10–20 mL/kg. However,
some evidence showed that this recommended dose has
not been efficient in correcting deficiencies of individual
coagulation factors whereas 30 mL/kg has been34.
Consequently, it is considered that transfusion of 1–2
FFP doses is absolutely inadequate (if not for pediatric
patients) and that a minimal therapeutic dose is 3 FFP
units or more (depending on body weight and on coagula-
tion deficit requiring correction). Our results have also
indicated that there was a statistically significant reduc-
tion of the total number of patients receiving 1 or 2 FFP
units, and a rise of those treated with 3 or more units in
the second period, thus improving the quality of transfu-
sion therapy.
In a study of Hui et al. a major indication for FFP
transfusion was the reversal of warfarin required to cor-
rect prolonged international normalized ratio. The sec-
ond reason for the use of FFP was massive transfusion35.
Recommendations given by some authors17 do not sup-
port the use of FFP in a massive transfusion unless it is
guided by a coagulation test. In our study, the largest
part of FFP went properly to patients with abnormal co-
agulation test results associated with bleeding, 61.5% in
the first period and 70% five years later, followed by mas-
sive transfusions 32.5% or 21.7% respectively, and the
least due to warfarin reversal only 6% or 8.3% respec-
tively. One of the possible reasons for such differences is
that the ambulatory for anticoagulation therapy is wi-
thin the Clinical Institute for Transfusion Medicine whe-
re such patients are regularly checked and in case of
overdose without signs of hemorrhagic diathesis they are
treated with vitamin K, and warfarin is discontinued in
compliance with the recommendations. It is interesting
to notice that the reasons for appropriate use of FFP
have not changed significantly throughout the examined
periods.
There are great discrepancies between the data of
performed laboratory coagulation tests (complete coagu-
logram) before FFP transfusion. Marti-Carvajal et al. re-
ported in 1999 that at the Venezuelan general university
hospital the prevalence of appropriate use of FFP was
only 26%, and in no case was a prior determination of the
patient’s coagulation deficiency made in order to decide
on the use of FFP12. Jones et al. has found that 88% of
the FFP issued showed reasons for treatment and pre-
and post-treatment coagulation results were available
for all patients36, while in other publication only 65.9%
had coagulation tests before FFP transfusion37. In our
study we found that most of the patients, 85.1% had
pretransfusion coagulation tests but in only 32.5% of pa-
tients were coagulation variables measured after trans-
fusion. The findings were similar in both studied periods.
The number of inappropriately treated patients was
reduced from 39.8% to 23.6%. Most of the patients (85.1%)
had coagulation tests done before FFP transfusion. The
number of patients transfused with 1 or 2 doses of FFP
decreased, while those treated with 3 or more increased.
The most frequent justified FFP transfusions were due
to coagulation disorders with bleeding, followed by mas-
sive transfusion and warfarin reversal.
We believe that these results are the consequence of
the introduction of clinical transfusion practice, educa-
tion, hemovigilance and good cooperation with other spe-
cialists who applied transfusion therapy in compliance
with the applicable guidelines and recommendations.
Numerous authors demonstrated that inappropriate FFP
transfusion was thus reduced38–40, which was also con-
firmed by our five-year experience.
High quality, efficient and safe transfusion therapy is
just a part of the entire health care. Therefore, an im-
proved quality of transfusion therapy has an impact on
health care in general and on the whole community, since
blood and drugs produced from blood are the national
treasure of each country.
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PROCJENA UPORABE SVJE@E SMRZNUTE PLAZME U KLINI^KOM BOLNI^KOM CENTRU RIJEKA
S A @ E T A K
Cilj rada bio je ispitati primjenu svje`e smrznute plazme (SSP) i kvalitetu transfuzijskog lije~enja bolesnika u dva
{estomjese~na razdoblja, u razmaku od 5 godina, prije i poslije uvo|enja standarda klini~ke transfuzijske prakse i sus-
tavnog nadzora transfuzijskog lije~enja (hemovigilance-a), te ocijeniti u~estalost i opravdanost primjene SSP u Klini-
~kom bolni~kom centru Rijeka i u~inke poduzetih mjera. Ispitano je 315 bolesnika lije~enih s 1341 dozom SSP, u raz-
doblju od rujna do velja~e 1999/2000. i 2004/05. godine. U prvom razdoblju retrospektivnom analizom transfuzijske
dokumentacije o izdavanju krvnih pripravaka ispitano je 226 bolesnika lije~enih s 928 doza SSP. U drugom razdoblju
prospektivno su pra}eni svi zahtjevi za transfuzijom SSP, opravdanost indikacija i izvr{eni koagulacijski testovi i anali-
zirano je 89 bolesnika transfundiranih s 413 doza SSP. Broj neopravdano lije~enih bolesnika smanjio se s 39,8% na
23,6%. Ve}ina bolesnika (85,1%) imala je u~injene testove zgru{avanja prije transfuzije SSP. Smanjio se broj bolesnika
transfundiranih jednom i dvije doze SSP, a pove}ao broj lije~enih s tri ili vi{e. Najvi{e adekvatno lije~enih bolesnika bilo
je zbog krvarenja uslijed koagulacijskog poreme}aja, zatim zbog masivnih transfuzija, a najmanje zbog poni{tavanja
djelovanja varfarina. Na{i rezultati ukazuju na smanjen broj bolesnika transfundiranih SSP u drugom razdoblju. Uo-
~en je povoljan u~inak uvo|enja standarda dobre klini~ke transfuzijske prakse i hemovigilance-a. Kako odre|eni broj
bolesnika nije trebao biti lije~en krvnim pripravcima, potrebno je nastaviti s zapo~etim, posebno s edukacijom svih
zdravstvenih djelatnika uklju~enih u transfuzijsko lije~enje.
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